Clinical validation of a plasma p ‐tau217 immunoassay and evaluation of the impact of kidney function

Abstract

Background: Blood‐based biomarkers have emerged as an accessible and lower cost alternative tool to support the diagnosis of Alzheimer disease. This study evaluated the clinical performance of a plasma p ‐tau217 immunoassay for identifying AD pathology as detected by amyloid positron emission tomography (PET).